164 related articles for article (PubMed ID: 27194485)
1. Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1.
Rajendran V
Mol Biosyst; 2016 Jun; 12(7):2276-87. PubMed ID: 27194485
[TBL] [Abstract][Full Text] [Related]
2. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate.
Sesanto R; Kuehn JF; Barber DL; White KA
Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606
[TBL] [Abstract][Full Text] [Related]
3. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H.
Yang B; Zhong C; Peng Y; Lai Z; Ding J
Cell Res; 2010 Nov; 20(11):1188-200. PubMed ID: 20975740
[TBL] [Abstract][Full Text] [Related]
5. Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
Kim HJ; Fei X; Cho SC; Choi BY; Ahn HC; Lee K; Seo SY; Keum YS
Bioorg Med Chem Lett; 2015 Dec; 25(23):5625-31. PubMed ID: 26508549
[TBL] [Abstract][Full Text] [Related]
6. Novel Insights for Inhibiting Mutant Heterodimer IDH1
Juritz EI; Bascur JP; Almonacid DE; González-Nilo FD
Mol Diagn Ther; 2018 Jun; 22(3):369-380. PubMed ID: 29651790
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
Avellaneda Matteo D; Wells GA; Luna LA; Grunseth AJ; Zagnitko O; Scott DA; Hoang A; Luthra A; Swairjo MA; Schiffer JM; Sohl CD
Biochem J; 2018 Oct; 475(20):3221-3238. PubMed ID: 30249606
[TBL] [Abstract][Full Text] [Related]
8. An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors.
Verdura S; Cuyàs E; Lozano-Sánchez J; Bastidas-Velez C; Llorach-Parés L; Fernández-Arroyo S; Hernández-Aguilera A; Joven J; Nonell-Canals A; Bosch-Barrera J; Martin-Castillo B; Vellon L; Sanchez-Martinez M; Segura-Carretero A; Menendez JA
Carcinogenesis; 2019 Mar; 40(1):27-40. PubMed ID: 30428017
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
[TBL] [Abstract][Full Text] [Related]
10. Structural studies of Saccharomyces cerevesiae mitochondrial NADP-dependent isocitrate dehydrogenase in different enzymatic states reveal substantial conformational changes during the catalytic reaction.
Peng Y; Zhong C; Huang W; Ding J
Protein Sci; 2008 Sep; 17(9):1542-54. PubMed ID: 18552125
[TBL] [Abstract][Full Text] [Related]
11. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y
Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149
[TBL] [Abstract][Full Text] [Related]
14. Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315.
Jakob CG; Upadhyay AK; Donner PL; Nicholl E; Addo SN; Qiu W; Ling C; Gopalakrishnan SM; Torrent M; Cepa SP; Shanley J; Shoemaker AR; Sun CC; Vasudevan A; Woller KR; Shotwell JB; Shaw B; Bian Z; Hutti JE
J Med Chem; 2018 Aug; 61(15):6647-6657. PubMed ID: 30004704
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
Ma T; Zou F; Pusch S; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
Bioorg Med Chem; 2017 Dec; 25(24):6379-6387. PubMed ID: 29089260
[TBL] [Abstract][Full Text] [Related]
16. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
[TBL] [Abstract][Full Text] [Related]
17. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.
Cuyàs E; Fernández-Arroyo S; Corominas-Faja B; Rodríguez-Gallego E; Bosch-Barrera J; Martin-Castillo B; De Llorens R; Joven J; Menendez JA
Oncotarget; 2015 May; 6(14):12279-96. PubMed ID: 25980580
[TBL] [Abstract][Full Text] [Related]
18. Identification of a new selective chemical inhibitor of mutant isocitrate dehydrogenase-1.
Kim HJ; Choi BY; Keum YS
J Cancer Prev; 2015 Mar; 20(1):78-83. PubMed ID: 25853107
[TBL] [Abstract][Full Text] [Related]
19. Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
Chambers JM; Miller W; Quichocho G; Upadhye V; Matteo DA; Bobkov AA; Sohl CD; Schiffer JM
Biochemistry; 2020 Feb; 59(4):479-490. PubMed ID: 31869219
[TBL] [Abstract][Full Text] [Related]
20. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]